Monoclonal antibodies (mAbs) have long provided powerful research tools for virologists to
understand the mechanisms of virus entry into host cells and of antiviral immunity. Even so …

Monoclonal antibodies (mAbs) are increasingly being considered as agents to fight severe
viral diseases. So far, they have essentially been selected and used on the basis of their …

Neutralizing antibodies play an essential part in antiviral immunity and are instrumental in
preventing or modulating viral diseases. Polyclonal antibody preparations are increasingly …

Antibodies are the principal immune effectors that mediate protection against reinfection
following viral infection or vaccination. Robust techniques for human mAb isolation have …

Antibodies are considered as an excellent foundation to neutralize pathogens and as highly
specific therapeutic agents. Antibodies are generated in response to a vaccine but little use …

A fascinating aspect of viral evolution relates to the ability of viruses to escape the adaptive
immune response. The widely held view has been that the great variability of viral …

Neutralizing antibodies (nAbs) are being increasingly used as passive antiviral reagents in
prophylactic and therapeutic modalities and to guide viral vaccine design. In vivo, nAbs can …

First, for rare or emerging diseases, such as Ebola, pandemic influenza or MERS-CoV,
demonstrating proof of concept in clinical trials is difficult. The small number of patients, the …

The natural human antibody response is a rich source of highly specific, neutralizing and
self-tolerant therapeutic reagents. Recent advances have been made in isolating and …

Antibodies have been used for more than 100 years in the therapy of infectious diseases,
but a new generation of highly potent and/or broadly cross-reactive human monoclonal …